As the first and only FDA-approved oral GLP-1 RA product, several studies have assessed the cost-effectiveness of semaglutide for treating T2DM in China, but none have compared its oral formulation with other GLP-1 RAs listed in China’s national medical insurance catalogue (Hu et al., 2021; Hu et al., 2022a; Hu et al., 2022b). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.